From bench to bedside: Exploring the role of sCD25 in melanoma and lung cancer among sleep apnea patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Díaz-García Elena, Alfaro Enrique, Pérez-Moreno Paula, López-Fernández Cristina, García-Sánchez Aldara, Martínez-García Miguel Ángel, Mañas Eva, Cano-Pumarega Irene, Casitas Raquel, Campos-Rodríguez Francisco, Sánchez-de-la-Torre Manuel, Nagore Eduardo, Martorell-Calatayud Antonio, Hernández Blasco Luis, Pastor Esther, Abad-Capa Jorge, Montserrat Josep María, Cabriada-Nuño Valentín, Corral-Peñafiel Jaime, Arias Eva, Mediano Olga, Somoza-González María, Dalmau-Arias Joan, Almendros Isaac, Troncoso-Acevedo Fernanda, Gotera-Rivera Carolina, Pérez-Warnisher Teresa, Peces-Barba Germán, Seijo Luis M, Gozal David, García-Rio Francisco, Cubillos-Zapata Carolina
Аннотация
MATERIALS AND METHODS: We investigated the plasma levels of soluble CD25 (sCD25) in three independent cohorts: patients with no evidence of cancer, with melanoma, and with lung cancer. We explored the role of hypoxaemia by intermittent hypoxia (IH) and HIF-1α inhibition in vitro models.
RESULTS: Our results suggest that sCD25 increases with hypoxemia severity in OSA, both with or without cancer. OSA patients also exhibit early upregulation of membrane-bound CD25 in T lymphocytes. Our findings corroborate that IH, via HIF-1α, mediates the upregulation of both membrane-bound and sCD25. sCD25 levels correlate with markers of melanoma and lung cancer aggressiveness, and elevated sCD25 levels are associated with higher lung cancer mortality risk.
CONCLUSION: Our study indicates that hypoxia mediates the increase of CD25 in OSA patients. In turn, our data revealed sCD25 were related to tumour aggressiveness in OSA patients with melanoma or lung cancer, and suggest sCD25 as a potential novel biomarker to stratify OSA patients with lung cancer by mortality risk.